Study finds middle age changes how brains respond to weight loss. Brain inflammation increased during dieting despite ...

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 Trial Builds on Recent Evidence of Persistent ...

Tiziana Life Sciences (TLSA) announces that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, ...

-- First Patient Expected to be Dosed Next Week with Intranasal Foralumab -- PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer's Patient on Leqembi (R) (Lecanemab) Anti-Amyloid ...

ABSTRACT: As a key process in maintaining cellular metabolic homeostasis, the targeted regulation of autophagy offers new insights into the treatment of metabolic disorders such as diabetes, obesity, ...

POTOMAC, MD / ACCESS Newswire / August 5, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging AI to develop innovative treatments ...

I rate INmune Bio, Inc. a speculative Strong Buy for high-risk investors, hinging on XPro's upcoming Phase II results in early Alzheimer's disease. XPro's unique mechanism targets neuroinflammation ...

Microglia are known to play an important role in Alzheimer's disease, but exactly what they do has remained a mystery. Scientists in the Bart De Strooper Lab at the VIB-KU Leuven Center for Brain & ...

Version of Record: This is the final version of the article. This paper reported a protocol of using human-induced pluripotent stem cells to generate cells expressing microglia-enriched genes and ...

Revised: This Reviewed Preprint has been revised by the authors in response to the previous round of peer review; the eLife assessment and the public reviews have been updated where necessary by the ...

As neuronal supporters and immune surveyors, astrocytes and microglia are no mere bystanders to the neuronal mayhem that unfolds in Alzheimer’s disease. At the AD/PD meeting, held March 5-9 in Lisbon, ...